PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
58 hedge funds and large institutions have $53M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $60M → $53M (-$7.02M)
Holders
58
Holding in Top 10
1
Calls
$239K
Puts
$1K
Top Buyers
| 1 | +$371K | |
| 2 | +$280K | |
| 3 | +$227K | |
| 4 |
BlackRock
New York
|
+$197K |
| 5 |
PTP
Platform Technology Partners
New York
|
+$162K |
Top Sellers
| 1 | -$5.92M | |
| 2 | -$175K | |
| 3 | -$84.1K | |
| 4 |
State Street
Boston,
Massachusetts
|
-$76.6K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$49K |